BioInvent is in a very attractive position with several value drivers.
BioInvent targets a commercially very attractive space in the pharmaceutical landscape – with potential to expand into new territories. BI-1206 is developed to re-establish the clinical effect of existing cancer treatments such as pembrolizumab and rituximab, drugs with combined global sales of approximately USD 23 billion annually. BI-1206 also has the potential to expand beyond the treatment of cancer. BioInvent has a strong deal-making track record, and has ongoing collaborations with companies such as CASI, Exelixis, Merck, Daiichi and Mitsubishi Tanabe.
All pharmaceutical development is associated with risk. BioInvent manages these risks by a stringent portfolio management, a diversified approach to drug candidates and mechanisms of action, and by targeting a very attractive space in the pharmaceutical landscape. Partnerships within the big pharma community, solid ownership and a strong cash position give BioInvent a solid platform to continue its transformation.
STRINGENT PORTFOLIO MANAGEMENT
BioInvent has several ongoing clinical programs, where each program has its own individual mechanism of action. In this way, the company is not dependent on the success of one individual program or one single technology. In the Discovery phase, BioInvent applies a stringent process in order to make sure that all of the company’s drug candidates have a smart design and high commercial potential for successful partnering at the optimal time for each project. The company’s Discovery engine not only generates new drug candidates, it also offers ample opportunity for successful collaborations and partnering.
BIG PHARMA PARTNERS AND SOLID OWNERSHIP
BioInvent has established partnerships with several big pharma companies, who not only contribute to the validation of the company’s clinical concepts but also has the financial strength to bring drug candidates to market. The company also has strong and long-term institutional specialist and generalist owners, something which brings stability and further enhances the ability to develop new and unique drug candidates. BioInvent also has a proven track record of
its financing activities and has a solid cash position, providing strength and flexibility in the continued transformation of the company.
BUSINESS MODEL
BioInvent has three main areas for commercialization. The Company’s primary value drivers are clinical and preclinical development projects. BioInvent also has research and development collaborations based on the Company’s technology platform F.I.R.S.T™ and its antibody library n-CoDeR®. BioInvent’s manufacturing facility provides capacity to produce antibodies for the Company’s preclinical studies and clinical trials, which is mandatory for a swift preclinical/ clinical development path. The manufacturing facility provides also the opportunity to manufacture and sell antibodies to external parties.